Cargando…

Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand

Objective: The aim of this study was to evaluate the cost-effectiveness of different glucosamine formulations and preparations used for the management of osteoarthritis in Thailand compared with placebo. Methods: We used a validated model to simulate the individual patient Utility score from aggrega...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruyère, Olivier, Detilleux, Johann, Reginster, Jean-Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059797/
https://www.ncbi.nlm.nih.gov/pubmed/36976312
http://dx.doi.org/10.3390/medicines10030023
_version_ 1785016960618070016
author Bruyère, Olivier
Detilleux, Johann
Reginster, Jean-Yves
author_facet Bruyère, Olivier
Detilleux, Johann
Reginster, Jean-Yves
author_sort Bruyère, Olivier
collection PubMed
description Objective: The aim of this study was to evaluate the cost-effectiveness of different glucosamine formulations and preparations used for the management of osteoarthritis in Thailand compared with placebo. Methods: We used a validated model to simulate the individual patient Utility score from aggregated data available from 10 different clinical trials. We then used the Utility score to calculate the quality-adjusted life year (QALY) over 3 and 6 months treatment period. We used the public costs of glucosamine products available in Thailand in 2019 to calculate the incremental cost-effectiveness ratio. We separated the analyses for prescription-grade crystalline glucosamine sulfate (pCGS) and other formulations of glucosamine. A cost-effectiveness cut-off of 3.260 USD/QALY was considered. Results: Irrespective of the glucosamine preparation (tablet or powder/capsule), the data show that pCGS is cost-effective compared with placebo over a 3 and 6 months. However, the other glucosamine formulations (e.g., glucosamine hydrochloride) never reached the breakeven point at any time. Conclusions: Our data show that pCGS is cost-effective for the management of osteoarthritis in the Thai context while other glucosamine formulations are not.
format Online
Article
Text
id pubmed-10059797
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100597972023-03-30 Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand Bruyère, Olivier Detilleux, Johann Reginster, Jean-Yves Medicines (Basel) Article Objective: The aim of this study was to evaluate the cost-effectiveness of different glucosamine formulations and preparations used for the management of osteoarthritis in Thailand compared with placebo. Methods: We used a validated model to simulate the individual patient Utility score from aggregated data available from 10 different clinical trials. We then used the Utility score to calculate the quality-adjusted life year (QALY) over 3 and 6 months treatment period. We used the public costs of glucosamine products available in Thailand in 2019 to calculate the incremental cost-effectiveness ratio. We separated the analyses for prescription-grade crystalline glucosamine sulfate (pCGS) and other formulations of glucosamine. A cost-effectiveness cut-off of 3.260 USD/QALY was considered. Results: Irrespective of the glucosamine preparation (tablet or powder/capsule), the data show that pCGS is cost-effective compared with placebo over a 3 and 6 months. However, the other glucosamine formulations (e.g., glucosamine hydrochloride) never reached the breakeven point at any time. Conclusions: Our data show that pCGS is cost-effective for the management of osteoarthritis in the Thai context while other glucosamine formulations are not. MDPI 2023-03-08 /pmc/articles/PMC10059797/ /pubmed/36976312 http://dx.doi.org/10.3390/medicines10030023 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bruyère, Olivier
Detilleux, Johann
Reginster, Jean-Yves
Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand
title Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand
title_full Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand
title_fullStr Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand
title_full_unstemmed Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand
title_short Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand
title_sort health technology assessment of different glucosamine formulations and preparations currently marketed in thailand
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059797/
https://www.ncbi.nlm.nih.gov/pubmed/36976312
http://dx.doi.org/10.3390/medicines10030023
work_keys_str_mv AT bruyereolivier healthtechnologyassessmentofdifferentglucosamineformulationsandpreparationscurrentlymarketedinthailand
AT detilleuxjohann healthtechnologyassessmentofdifferentglucosamineformulationsandpreparationscurrentlymarketedinthailand
AT reginsterjeanyves healthtechnologyassessmentofdifferentglucosamineformulationsandpreparationscurrentlymarketedinthailand